CAS: 51535-00-3; Methyl 1-Benzyl-5-Oxo-3-Pyrrolidinecarboxylate

上下游产品

CAS号617-52-7 衣康酸二甲酯 | CAS号100-46-9 苄胺 | CAS号57402-97-8 1-phenyl-N-(tri... | CAS号624-48-6 顺丁烯二甲酸二甲酯 | CAS号67-56-1 甲醇 | CAS号5733-86-8 1-苄基-5-氧代-3-吡咯烷甲酸 | CAS号100-52-7 苯甲醛 | CAS号108303-96-4 dimethyl 2-((be... | CAS号97-65-4 衣康酸 | CAS号5733-86-8 1-苄基-5-氧代-3-吡咯烷甲酸 | CAS号368429-72-5 1-苯基-5-氧代-3-吡咯烷羰酰肼 | CAS号368429-69-0 4-氨基-1-苄基吡咯烷-2-酮 | CAS号216311-60-3 (S)-甲基吡咯烷-3-甲酯 | CAS号303111-43-5 (R)-1-苄基-beta-脯氨醇 | CAS号315718-05-9 1-CBZ-3-羟甲基吡咯烷 | CAS号98548-90-4 3-吡咯烷甲酸甲酯 | CAS号78914-69-9 (s)-(1-苄基-吡咯烷-3... | CAS号5731-17-9 1-苄基吡咯烷-3-甲醇 | CAS号72925-16-7 |R|-1-B°C-3-羧基吡咯烷

📜Dimethyl 2-[(Benzylideneamino)Methyl]Butanedioate置于sodium Tetrahydroborate体系中,用 甲醇 作为反应溶剂,化学反应生成 1-苄基-5-氧-3-吡咯烷羧酸甲酯
参考文献:N-(甲硅烷基甲基)亚胺的合成多功能性:水诱导反应生成非稳定型 N-质子化偶氮甲碱叶立德和氟化物诱导反应生成 2-氮杂烯丙基阴离子
标题:N-(甲硅烷基甲基)亚胺的合成多功能性:水诱导反应生成非稳定型 N-质子化偶氮甲碱叶立德和氟化物诱导反应生成 2-氮杂烯丙基阴离子
摘要:N-(甲硅烷基甲基)亚胺在 Hmpa 中用水处理时会反应生成 N-质子化的非稳定型偶氮甲碱叶立德,该亚胺会发生立体有择性和区域选择性环加成反应,并带有电子磷...
DOI:10.1246/bcsj.59.2537

专利信息

专利号:US-5939392-A
优先权日:1993-06-03
标 题 :Method of thrombin inhibition
发明人：ANTONSSON KARL THOMAS; BYLUND RUTH ELVY; GUSTAFSSON NILS DAVID; NILSSON NILS OLOV INGEMAR
权利人:ASTRA AB
摘要:The invention relates to new competitive tripeptide inhibitors of trypsin-like serine proteases, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as thrombin inhibitors, anticoagulants and antiinflammatory inhibitors for prophylaxis and treatment of related diseases.

专利号:US-8252930-B2
优先权日:2006-07-06
标 题:Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
发明人：STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G
权利人:STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G; SOLVAY PHARM BV
摘要:Azaindole derivatives of formula (I): n nwherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.

专利号:US-5723444-A
优先权日:1993-06-03
标 题:Starting materials in the synthesis of thrombin and kinogenase inhibitors

专利号:EP-2041131-B1
优先权日:2006-07-06
标 题 :Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
发明人：STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G
权利人:ABBOTT HEALTHCARE PRODUCTS BV
摘要:The invention concerns azaindole derivatives having the general formula (I) wherein the symbols have the meanings given in the specification. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.

专利号:US-5780631-A
优先权日:1993-06-03
标题 :Starting materials in the synthesis of thrombin and kininogenase inhibitors

专利号:US-6214832-B1
优先权日:1997-06-18
标 题 :Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; BOCK MARK G
权利人:MERCK & CO INC
摘要:Pyrimidinone, oxazolidinone, and (alkyl)aryl derivatives, their synthesis, and their use as alpha 1a adrenergic receptor antagonists are disclosed. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved. Among the disclosed derivatives are piperidinyl aminoalkylpiperidinyl pyrimidinones, including those of formula:R1 is selected from unsubstituted, mono- or poly-substituted phenyl wherein the substituents on the phenyl are independently selected from halogen, CF3, cyano, nitro, N(R7)2, NR7COR19, NR7CON(R19)2, NR7SO2R19, NR7SO2N(R19)2, OR6, (CH2)0-4CO2R7, (CH2)0-4CON(R7)2, or C1-4 alkyl; or unsubstituted, mono- or poly-substituted pyridyl, pyrazinyl, thienyl, thiazolyl, furanyl, quinazolinyl or naphthyl wherein the substituents on the pyridyl, pyrazinyl, thienyl, thiazolyl, furanyl, quinazolinyl or naphthyl are independently selected from CF3, cyano, nitro, amino, (CH2)0-4CO2R7, (CH2)0-4CON(R7)2, (CH2)0-4SO2N(R7)2, (CH2)0-4SO2R6, phenyl, OR6, halogen, C1-4 alkyl or C3-8 cycloalkyl;m and p are each integers from zero to two, wherein the sum m+p=2; n and o are each integers from zero to two, wherein the sum n+o=2; q is an integer of from zero to three, provided that when q is zero, R26 is hydrogen; s is an integer of from zero to four; andE, G, J, L, M, W, X, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R16, R19 and R26 are defined herein.